for people ages 18 years and up (full criteria)
at Sacramento, California and other locations
study started
estimated completion



The purpose of this study is to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week 54.

Official Title

A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy


Proliferative Diabetic Retinopathy proliferative diabetic retinophathy, retinal neovascularization, anti-VEGF, brolucizumab, intravitreal injection, panretinal photocoagulation Retinal Diseases Diabetic Retinopathy Brolucizumab 6 mg Panretinal photocoagulation laser


You can join if…

Open to people ages 18 years and up

  1. Signed informed consent must be obtained prior to participation
  2. Able to complete adequate fundus photographs and retinal images
  3. Diagnosis of type 1 or 2 Diabetes Mellitus (DM) and HbA1c less than or equal to 12% at screening
  4. DM treatment stable for at least 3 months
  5. PDR diagnosis with no previous PRP treatment in the study eye

You CAN'T join if...

  1. Concomitant conditions or ocular disorders in the study eye at Screening or Baseline that could compromise a response to study treatment.
  2. Presence of diabetic macular edema in the study eye Active infection or inflammation in the study eye
  3. Uncontrolled glaucoma (IOP greater than 25 mmHg)
  4. Intravitreal anti-VEGF treatment within 6 months
  5. Treatment with intraocular corticosteroids
  6. End stage renal disease requiring dialysis or kidney transplant
  7. Uncontrolled blood pressure
  8. Systemic anti-VEGF therapy at any time Other protocol-defined inclusion/exclusion criteria may apply -


  • Novartis Investigative Site accepting new patients
    Sacramento California 95817 United States
  • Novartis Investigative Site accepting new patients
    Rancho Cordova California 95670 United States


accepting new patients
Start Date
Completion Date
Novartis Pharmaceuticals
Sign up for this study
Phase 3
Study Type
Last Updated